Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma

NCT01729806 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01729806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01729806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
November 19, 2012
Completion date
March 30, 2018
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cd20 positive, recurrent b-cell non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma